Please assess the completion status of the following clinical trial:

Trial Title: Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven mycosis fungoides or Sezary syndrome~  * Any stage~* Measurable disease with 1 or more indicator lesions~  * Evaluable disease for erythrodermic patients only~* At least 2 weeks since prior therapy, if documented progressive disease (PD)~* At least 4 weeks since prior therapy, if best response achieved without clear evidence of PD~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* At least 3 months~Hematopoietic:~* WBC at least 3,000/mm\^3~* Absolute granulocyte count at least 1,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.2 mg/dL~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No New York Heart Association class III or IV heart disease~* No cardiac pacemaker~* No clinically significant peripheral venous insufficiency~Other:~* No other malignancy within the past 5 years except:~  * Treated squamous cell or basal cell skin cancer~ * Treated carcinoma in situ of the cervix~ * Surgically treated other cancer~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No active infection~* HIV negative~* No poorly controlled diabetes mellitus~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~Endocrine therapy:~* No concurrent steroids~Radiotherapy:~* See Disease Characteristics~* No concurrent radiotherapy~Surgery:~* Not specified~Other:~* No other concurrent proven or investigational antineoplastic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).